Shorla Oncology announces FDA approval of a new 375 mg vial of Nelarabine, addressing critical dosing gap for adult and pediatric patients living with T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma.
Shorla Oncology announces FDA approval of a new 375 mg vial of Nelarabine, addressing critical dosing gap for adult and pediatric patients living with T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma.
